Board of Directors
Dr. Bloch is a General Partner at Canaan Partners. As an early investor and chairman, Dr. Bloch helped Advanced BioHealing (ABH), a leader in regenerative medicine, grow from a seed-stage company to a $750 million all-cash acquisition by Shire. He currently serves on the boards of companies in healthcare IT (Truveris and Ambra Health); biopharma (Envisia and Liquidia); medical devices (Mitraspan); and diagnostics (Sample6). Before joining Canaan in 2002, Dr. Bloch founded multiple start-ups, including Radiology Management Sciences (RMS), a specialty medical management company, where he was CEO for 6 years. Dr. Bloch obtained his B.A. from Dartmouth College, received his M.A. in the history of science and public policy from Harvard, and he earned his medical degree from the University of Rochester. Dr. Bloch received his medical training at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).
Mr. deGoa was CEO of RareGen, LLC, a rare disease commercial company until its merger with Liquidia. Previously, Mr. deGoa was CEO of Breas Medical Group, a global respiratory medical device company, headquartered in Sweden, until its sale to Fosun Pharma. Since 2012, Mr. deGoa was a Managing Director/Partner at PBM Capital Group, a healthcare investment firm where he was responsible for M&A and executive leadership at portfolio companies like RareGen and Breas. Mr. deGoa started his career in the healthcare industry with Perrigo Company holding various roles including corporate development, international business development, and divisional finance lead. Mr. deGoa holds a BA from the University of Michigan and a MBA from Depaul University.
Dr. Horobin has more than 30 years of successful pharmaceutical development experience. She was most recently Senior Vice President and Chief Medical Officer at Idera Pharmaceuticals, Inc. Prior to that, she held positions as Chief Medical Officer at Verastem, Inc., CEO of Syndax Pharmaceuticals, Inc. and several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi). Dr. Horobin played significant leadership roles in the approvals of several prominent drugs across a breadth of therapeutic indications including oncology, cardiology, pulmonary, antibacterial and chronic pain. Dr. Horobin received her medical degree from the University of Manchester, England. She currently serves on the boards of Kymera Therapeutics and Nordic Nanovector ASA.
Roger Jeffs retired as President and co-CEO at United Therapeutics in 2016 after a successful 18-year tenure. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as Director of Research, Development, and Medical, and served as the company’s President and Chief Operating Officer from 2001 to 2014 and President & co-CEO from 2015-2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs previously served on the Board of Directors for United Therapeutics, Dova Pharmaceuticals, and Sangamo Therapeutics and currently serves on the Boards of Albireo Pharma, and Axsome Therapeutics.
Mr. Kirsch is Director and Senior Advisor, as well as global head of medical devices and diagnostics, of GCA Global, LLC, a global investment banking firm. Mr. Kirsch has been focused on both M&A and Capital Markets transactions within the healthcare industry for the past 20 years. Mr. Kirsch’s experience spans advising both public and private companies with extensive knowledge of cross border transactions between the U.S. and Asia. Prior to joining GCA Global, he was a executive vice president, head of research at Vector Securities. Previously, Mr. Kirsch was president of Natwest Securities Limited, a foreign owned investment bank. Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert and eventually became head of the Equity Division and a member of the firm’s Executive Committee. He serves as Chairman of the Board of Directors at Aralez, Inc. a public biopharmaceutical company where he is also Chairman of the Audit Committee. Mr. Kirsch earned a B.S. in Finance at the University of Rhode Island and an MBA from The City University of New York.
Mr. Manning is the President and CEO of PBM Capital Group based in Charlottesville, VA. An entrepreneur with thirty years of experience in the healthcare industry, Mr. Manning founded PBM Capital Group in 2010, a private equity investment firm in the business of investing in health care and life-science related companies. Mr. Manning directs all investment decisions and sits on the board of directors for many of PBM Capital’s investments including: Avexis (NASDAQ:AVXS), Dova Pharmaceuticals, Verrica Pharmaceuticals, and PBM Pharmaceuticals. Mr. Manning has successfully founded several companies that developed and distributed prescription and over the counter products to major chains in the United States. In 1997, Mr. Manning founded PBM Products, which became the largest private label producer of infant formula and baby/toddler food in the world. PBM Products was sold to Perrigo Corporation in 2010. Mr. Manning served on Perrigo Corporation’s Board of Directors after the sale. Mr. Manning is an active member of the University of Virginia community, having served on the Board of UVA Strategic Planning Committee, the Board of UVA Health Foundation, and the Board of the President’s Advisory Committee. Mr. Manning graduated from the University of Massachusetts with a B.S. in Microbiology. Mr. Manning was named Virginia Entrepreneur of the Year by Ernst and Young in 2002.
Ms. Rielly-Gauvin is currently Vice President of Global Commercial Development at AbbVie and brings 20 years of diverse pharmaceutical industry experience to Liquidia’s Board. At AbbVie, she is responsible for developing the strategic commercial direction of key compounds in the company’s pipeline across core therapeutic areas in Immunology, Oncology, Neuroscience and Specialty. Previously, Ms. Rielly-Gauvin worked in the Johnson & Johnson family of companies in commercial, medical affairs and research capacities, including Vice President and General Manager for the Janssen Commercial CNS organization. She holds a B.S. in Chemistry from Simmons College and an MBA in Economics from Rutgers University.
Mr. Singh is Chief Executive Officer of Mundipharma Pte Limited, which is part of a network of independent associated companies active in the fields of respiratory, oncology, pain and biosimilars. Prior to joining Mundipharma Pte Limited in October 2011, Mr. Singh served as vice president of commercial operations for emerging markets at GSK. In his role, he oversaw all aspects of the brand’s commercial operations across its emerging markets. Mr. Singh has previously held positions at Abbott as the regional director in Australia and New Zealand, and general manager for Korea, as well as various sales, marketing and strategy positions at Bayer. Mr. Singh graduated with a Bachelors in Mechanical Engineering. He also holds Masters of Business Administration from Assumption University and Masters in International Management from Thunderbird School of International Management. He is a brand ambassador for the Singapore Tourism Board, and a governor of the World Economic Forum, Global Health and Healthcare Committee and a part of the advisory board at Manchester City Football Club.